Scientific cooperation

National

  • Dr. Monika Bieniecka, Kardio-Med Silesia, Zabrze;
  • Prof. Marian Zembala, Dr. Michał Zembala, Silesian Center for Heart Diseases in Zabrze;
  • Prof. Anna Kostera-Pruszczyk, Clinic of Neurology, Warsaw Medical University, Warsaw;
  • Prof. Elżbieta Pyza, Institute of Zoology, Jagiellonian University, Kraków;
  • Prof. Krzysztof Sładek, Prof. Marek Sanak, Prof. Rafał Niżankowski, 2nd Clinic of Internal Medicine, Collegium Medicum, Kraków.

 

International

  • Prof. Claudine Kieda, Prof. Eva Jakab-Toth, Prof. Chantal Pichon, Dr. Patrick Midoux, CNRS & University of Orleans, France;
  • Prof. Mauro Giacca, ICGEB, Trieste, Italy & King’s College, London, UK;
  • Prof. Irving Weissman, Stanford University, CA, USA;
  • Dr. Roberto Motterlini, Dr. Roberta Foresti - INSERM U955; Faculty of Medicine; Henri Mondor Hospital; University Paris-Est, France.

 

Industrial cooperation

  • Selvita, Krakow, Poland – anti-cancer drugs;
  • Adamed, Czosnow, Poland: anti-diabetic drugs & anti-cancer drugs;

 

Grants in cooperation:

  • European Commission - Horizon 2020 Programme - Humanized high-throughput co-culture system for motor neuron diseases, NMJ-on a -Chip (2020-2023), funded by the National Science Centre, Poland under JPco-fuND 2, This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 825664 – JPco-fuND 2, coordinate by Tel Aviv University, Israel.
  • European Commission - Horizon 2020 Programme - Heart on Chip based on induced pluripotent Stem Cell Technology for personalized Medicine - CISTEM consortium (2018-2021) coordinated by BioSense Institute (Novi Sad, Serbia).
  • The National Centre Research and Development - Applied Research Programme - New inhibitors of heme oxygenase-1 as potential anticancer drugs - HEMOKS 2014-2017 - consortium composed of: Department of Medical Biotechnology JU and Selvita.
  • The National Centre Research and Development - STRATEGMED Programme - Mesenchymal stem cells and MSC-enriched scaffold as an alternative therapy for myocardial insufficiency - PHOENIX 2015-2018 – consortium composed of: Silesian Center for Heart Diseases in Zabrze, Professor Zbigniew Religa Cardiac Surgery Development Foundation, Kardio-Med Silesia, American Heart of Poland, Adamed, The University of Dublin Trinity College and Department of Medical Biotechnology JU.
  • The National Centre Research and Development - STRATEGMED Programme - Epigenetic Therapies in Oncology - EPTHERON 2015-2018, consortium composed of Selvita, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Institute of Hematology and Transfusion Medicine, Nencki Institute of Experimental Biology PAN, Department of Medical Biotechnology Faculty BBB and Malopolska Centre of Biotechnology JU, Wrocław University of Technology.

 

Patents

  • Cobalt porphyrins for the treatment of blood-related disorders. Agata Szade, Krzysztof Szade, Alicja Józkowicz, Józef Dulak.  United States Patent and Trademark Office  patent no. US10010557 (03.07.2018) and US10328085 (25.06.2019)
  • Cobalt protorphyrin IX for the treatment of blood-related disorders. Agata Szade, Krzysztof Szade, Alicja Józkowicz, Józef Dulak. European Patent Ofiice patent no. EP 3139917 (03.07.2019)
  • Protoporfiryna IX kobaltu do stosowania w leczeniu neutropenii i białaczek. Urząd Patentowy Rzeczypospolitej Polskiej, Patent no 233504 (26.11.2019)